California-based AI drug discovery company PostEra has announced a multi-year strategic partnership with the pharma giant Pfizer to accelerate small molecule drug discovery.
PostEra will develop a generative chemistry-based platform by utilizing Pfizer’s extensive data and expertise to be deployed across in-house, preclinical drug discovery programs.
PostEra will receive an undisclosed upfront payment and is also eligible for additional milestone payments. Ownership rights of any algorithms developed during the partnership will belong to PostEra.
Founded in 2019, PostEra is a University of Cambridge spin-out company engaged in utilizing machine learning technology to design novel molecular structures. Its approach is based on combining chemical synthesis with molecular designing. In addition to collaborating with drug developers, it also operates a chemical database, Manifold, to offer some of its synthesis technology.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.